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Abstract
Background: Salvage surgery has been recommended as the approach of choice for neck residue or recurrence of
nasopharyngeal carcinoma (NPC) after primary radiotherapy (RT). This study aimed to assess the outcome and
prognostic factors, options for different surgical methods, and the extent of neck dissection (ND) for patients.
Methods: NPC patients who had undergone RT and received salvage surgery for neck residue or recurrence from
January 2001 to December 2011 were retrospectively analyzed. The overall survival (OS) rate was calculated by
Kaplan-Meier method, and prognostic factors were determined by log-rank test and Cox regression analysis.
Results: In 153 cases, 96 cases have level I dissections. The metastasis rate was 20/153 (13.07 %) for level I
metastasis and 7/153 (4.58 %) for parotid gland cases. The 3- and 5-year OS rate was 57.2 and 40.6 %, respectively,
and median survival time was 49 months. By univariate analysis, the age, rN staging, size of lymph nodes (LN),
extra-capsular spread (ECS), and surgical procedure were significant prognostic factors. By multivariable analysis,
the age, rN staging, and size of LN were significant prognostic factors.
Conclusions: Salvage surgery is effective for neck failure of NPC after primary treatment, but patients with
age >50 years, stage rN3, or LN >6 cm have poor prognosis.
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Background
Nasopharyngeal carcinoma (NPC) is a prevalent disease
in southern China with unique epidemiology, path-
ology, and treatment outcome [1]. Radiotherapy (RT)
or chemoradiotherapy (CRT) has been standard treat-
ment for newly diagnosed NPC [2, 3]. But for residual
or recurrent NPC, surgery is needed [4]. NPC is easy to
metastasize to cervical lymph nodes (LN), and the inci-
dence of residual or recurrent NPC is 4.6–18 % [5–7].
Neck dissection (ND) has been proposed for poor out-
comes after primary NPC treatment.
After primary treatment, regional neck disease of NPC
is prone to extra-capsular spread (ECS). Therefore,
radical neck dissection (RND) is proposed for the con-
trol of regional NPC [8–11]. Despite the development of
surgical technique, the surgical traumas and complica-
tions remain. Currently, the preservation of the internal
jugular vein, sternocleidomastoid muscle, and/or spinal
accessory nerve and even selective cervical neck dissec-
tions to protect external jugular vein and cervical plexus
have been widely performed in head and neck squamous
carcinoma and thyroid cancer. Modified radical neck dis-
section (MRND) for preserving the internal jugular vein,
sternocleidomastoid muscle, and/or spinal accessory nerve
is technically feasible. However, whether MRND could
improve survival rate of patients and minimize surgical
morbidity remains unclear.
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In this study, we retrospectively reviewed the medical
records of patients with neck regional failure after
primary NPC treatment to assess different surgical
methods and the extent of neck dissection for neck
residue or recurrence of NPC after primary RT. We also
analyzed prognostic factors on treatment outcomes such
as regional control and overall survival.
Methods
Patients
The study protocol was approved by Ethics Committee
of Zhejiang Cancer Hospital. This retrospective study
included 153 patients, who had previously undergone
RT with or without chemotherapy, had untreated neck
residue or recurrence of NPC with no evidence of local
disease and distant metastases, and then were treated
with salvage surgery. All patients underwent neck dissec-
tion at the Department of Head and Neck Surgery,
Zhejiang Cancer Hospital, from January 2001 to December
2011. There were 128 males and 25 females. The median
age was 49 years (ranged from 18 to 76 years) at the time
of treating for neck regional recurrence or residue.
NPC patients were treated with standard RT, which
consisted of 65–78 Gy to primary tumor, 60–70 Gy to
involved LN, 50 Gy to uninvolved neck, and daily dose
1.8–2.0 Gy/5 days a week. One hundred thirty-one NPC
patients got additional chemotherapy. Regional NPC re-
currence was confirmed by fine-needle aspiration (FNA)
or open biopsy. All neck metastases were pathologically
identified after the surgery. Before receiving salvage
treatment for regional failure, all patients received
complete physical examination, nasopharyngoscopy and
biopsy of suspicious nasopharyngeal lesions, magnetic
resonance imaging (MRI) scans and/or computed tom-
ography (CT) of nasopharynx and neck, CT or X-ray of
chest, color Doppler ultrasound of abdominal and neck,
and bone scanning were carried out to exclude local
disease and distant metastases.
Tumor characteristics
Recurrent disease was defined as the reappearance of
cervical LN 3 months after initial complete regression,
and residual disease was defined as the lymph nodes
without complete regression by 3 months after primary
therapy as described previously [9]. The group with re-
current nodal disease consisted of 105 patients (68.6 %),
while the group with residual nodal disease consisted of
48 patients (31.4 %). The interval between the finishing
time of RT/CRT and cervical relapse was from 4 to
192 months (median, 30 months).
Among the 153 patients, 109 patients were stage rN1,
17 were stage rN2, and 27 were stage rN3, according to
the 2002 American Joint Committee on Cancer (AJCC)
Classification staging system [12]. Sixty-eight cases were
left, 68 cases were right, and 17 cases were bilateral. Ac-
cording to the lymph nodal sites, level II was the most
common site of nodal involvement, followed by levels V,
III, IV, and I. In level II, 122 cases (79.7 %) had LN
metastasis. Twenty cases (13.1 %) had LN metastasis in
level I and 7 cases (4.6 %) had parotid gland metastasis.
Pathological analysis of surgical specimens showed that
111 tumors (72.5 %) had ECS.
Follow-up
The patients were followed up by visiting hospital for
evaluation of recurrence every 3 months. They were
followed up by phone call or letter for survival if they
failed to visit the hospital. The starting point of the
follow-up period was defined as the completion of
salvage treatment for regional recurrence or residue,
while the end point was defined as when the patient died
or June 2013.
Statistical analysis
Data were analyzed by using SPSS 16.0 software (SPSS
Inc, Chicago IL, USA). Overall survival rate was calcu-
lated by Kaplan-Meier method. The differences between
groups were analyzed by chi-square test, and the statis-
tical significance of regional control was determined
using logistic regression. P < 0.05 was considered signifi-
cant difference.
Results
Modality of salvage treatment
All 153 patients received neck dissection as salvage
surgery for neck regional failure after primary NPC
treatment at the Department of Head and Neck
Surgery, Zhejiang Cancer Hospital. Seventeen patients
received bilateral ND simultaneously, so totally, 170
cases had ND on the lateral basis. The classification
of ND was as follows: 84 laterals received ND for
levels I–V, 44 for levels II–V, 17 for levels I–III, 9 for
cervical local excision, 5 for levels I–II, 2 for levels
II–VI, 2 for levels III–V, 3 for parotidectomy, 2 for
totally parotidectomy + levels I–II, 2 for levels I–V +
parotidectomy. Seven patients were treated with the
removal of ipsilateral parotid LN and total or partial
parotidectomy. The surgical procedures taken were as
follows: 106 patients received MRND (including SND
in 28, local excision in 9, and parotidectomy in 3), 48
patients received RND, and 16 patients received
enlarged radical neck dissection (ERND). ND was
performed via different approaches based on the char-
acteristics of the diseases (Table 1).
For MRND, 64 cases had total preservation of the
internal jugular vein, sternocleidomastoid muscle, and
spinal accessory nerve, 18 cases had preservation of the
internal jugular vein and spinal accessory nerve, 5 cases
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had preservation of the internal jugular vein and sterno-
cleidomastoid muscle, 16 cases had preservation of the
internal jugular vein, and 3 cases had preservation of
the spinal accessory nerve. For ERND, 12 cases had the
skin involved, 4 cases had the phrenic nerve involved, 2
cases had the carotid artery involved, 2 cases had the
vagus nerve involved, 2 cases had the submaxillary
involved, and 1 case had the hypoglossal nerve in-
volved. Twenty-five cases underwent pedicled pectora-
lis major muscle flap surgery. Among 153 patients, 10
received postoperative re-RT and 23 received combin-
ation of chemotherapy.
Survival analysis
During the follow-up period of 2 to 147 months
(median 29 months), 74 of 153 patients were alive,
while 79 patients died. Kaplan-Meier survival ana-
lysis indicated that total 3-year OS was 57.2 % and
5-year OS was 40.6 %. The median survival time
(MST) was 49 months (Fig. 1). Univariate analysis showed
that the age, rN staging, size of LN, ECS, and surgical pro-
cedure were significant factors affecting the survival rate
(P < 0.05). Cox analysis revealed that the age, rN staging,
and size of LN were the main factors affecting the survival
rate (Tables 2 and 3).
Regional control
In follow-up, regional recurrence or failure was noted in
21 (13.7 %) patients: 12 had ipsilateral neck recurrence,
3 had ipsilateral parotid region relapse, 2 had ipsilateral
parapharyngeal lymph node relapse, 2 had oral cavity
and oropharynx secondary primary carcinoma, 1 had
nasopharyngeal carcinoma relapse, and 1 had contralateral
neck recurrence. The relapse time was 2 to 38 months
(median 12 months).
Distant metastasis
Twenty-nine patients (19.0 %) developed distant metas-
tasis 6 to 48 months after treatment. Among them, 8
cases survived with tumor, while 2 cases died. The most
common site of metastasis was the lung (18), followed
by the liver (9), bone (8), abdominal cavity (3), mediasti-
num (3), and axillary nodes (2).
Complications
After surgery, there was no surgical mortality in any
patients, but several complications were observed as
follows: incision infection (6 cases), debridement due to
disruption of wound or flap necrosis (5 cases), chylous
linkage (4 cases), post-operational bleeding (2 cases),
deviated mouth (2 cases), hoarseness (2 cases), bucking
(2 cases), Horner’s syndrome (2 cases), injury of hypo-
glossal nerve (1 case), prosopoplegia (1 case), and
induced or aggravated radiation encephalopathy (1 case).
Discussion
NPC is a common tumor of the head and neck that is
prevalent in southern China. RT/CRT rather than
surgery is the primary treatment for NPC, due to the
anatomical location and the radiosensitivity of the
tumor. Despite regional control by RT/CRT, NPC has a
tendency to metastasize to cervical LN and the incidence
of residual or recurrent NPC is 4.6–18 % [6, 7]. There is
still a problem with how to approach failures associated
with the first treatment for neck lesion.
Most regional persistent or recurrent disease is tech-
nically resectable and is usually salvaged surgically.
Thus, salvage surgery is important for the treatment of
recurrent nodal disease [8, 9, 13]. Zhang et al. used
salvage ND to treat 355 NPC patients who were diag-
nosed with neck residue or recurrence after RT, and the
3-and 5-year OS was 54.11 and 26.03 %, respectively
[14]. In this study, we retrospectively reviewed 153
patients with NPC, the 3-year and 5-year OS was 57.2
and 40.6 %, respectively; and MST was 49 months after
salvage surgery for neck residue or recurrence. Furthermore,
Table 1 Characteristics of NPC undergoing MRND and
RND/ERND
Characteristic Cases observed Surgical procedure χ2 value P
MRND (89) RND/ERND (64)
Age (year)
≤50 90 55 35
>50 63 34 29 0.777 0.378
Gender
Male 128 74 54




Residue 48 35 13 6.251 0.012
rN stage
N1 109 79 30
N2 17 8 9
N3 27 2 25 38.625 0.000
Size of LN
≤3 cm 80 68 12
3~6 cm 47 20 27
>6 cm 26 1 25 59.911 0.000
ECS
Yes 111 47 64
No 42 42 0 41.630 0.000
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we determined that the age, rN staging, and size of LN are
the factors that affect survival rate. In this cohort, the
prognosis of patients with age ≤50 years old was better
than patients with age >50 years old. The reason is un-
known but may be due to that younger patients are much
more apt to intensive treatment.
Currently, there are still no uniform standards on the
options of surgical methods and regions for ND. The
extent of surgical resection might range from excision of
the enlarged node to SND, MRND (removing all the
lymphatic tissue and LN in the neck while preserving
non-lymphatic structures such as the internal jugular vein,
sternocleidomastoid muscle, and/or spinal accessory
nerve), and RND to ERND. The type of salvage surgery
depends on the pathological aspects of metastatic
NPC in the LN. Residual lymph nodes after NPC
radiation tend to be highly malignant and invasive
and have a high incidence of ECS to the non-
lymphatic structure. RND is suggested to be the opti-
mal treatment choice to remove neck disease, and it
has become the mainstay of treatment for regional
failure of NPC [15–17]. However, RND may impair
daily activities of the patients because the sacrifice of
the spinal accessory nerve would cause shoulder pain,
and the ligation of the internal jugular vein would cause
facial swelling [18]. In contrast, MRND gets rid of all
lymphatic tissues of the neck but preserves the spinal
accessory nerve, sternocleidomastoid muscle, and/or
internal jugular vein, reducing surgical morbidity.
In this study, we performed surgery on 153 patients,
with 170 cases of cervical dissections on the lateral basis.
Among them, 106 cases received MRND. MRND could
reduce surgical morbidity and complications such as
shoulder pain and facial swelling and thus improve the
quality of life of the patients. Meanwhile, RND is the
appropriate approach for isolated regional failure of
NPC, especially when NPC is advanced or the spinal
accessory nerve and internal jugular vein are involved.
There are several complications after NPC cervical
radiation, such as tissue fibrosis, muscle atrophy and
ischemia of the skin. So we could selectively use myo-
cutaneous flap with vessel pedicle such as pedicled
pectoralis major muscle flap in RND after NPC radio-
therapy. The merits of this surgery are as follows:
rapid postoperative recovery, enough tissue to select,
powerful anti-infection ability, easy to close dead
space, protecting large vessels such as carotid artery,
and avoiding serious complications. In this study, 25
cases had surgery of pedicled pectoralis major muscle
flap, and the outcomes were satisfied without flap
necrosis after flap transpositions.
Early reports suggest that RND should be adopted
when cervical LNs recur after NPC radiotherapy.
RND ranges over complete excisions of the whole
tissues including the sternocleidomastoid muscle,
internal jugular vein, accessory nerve, accessory nerve,
submandibular gland, inferior portion of the parotid
gland, and peripheral lymphoid tissues. Sham et al.
reported distributing characteristics of cervical LNs in
NPC; the metastasis rate of levels I, II, III, IV, and V
was 12.7, 95.4, 60.2, 15.5, and 44.0 %, respectively.
The metastasizing region was mainly focused on level
Fig. 1 The survival curve of patients undergoing salvage surgery with the diagnosis of neck recurrence or residue of nasopharyngeal carcinoma.
X axial: survival time (months); Y axial: cumulative survival rate
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II, and level I had the lowest metastasis rate [19].
Yen et al. reported that the incidence of cervical
recurrence of NPC was 81 % at levels II and V, while
the relapse rate was much lower for levels I and III,
and they suggested that NRD surgery of NPC should
mainly concentrate on levels II and IV [10].
In this cohort of 153 cases, level II was the highest
nodal metastasis site (79.7 %). Level II should be
considered as an important dissected region. Metasta-
sis nodes in levels III to V are always distributed
multiregionally, melting together and hardly distin-
guished by separate level. In our study, 96 cases had
level I dissection. The total relapse rate of case at
level I was 13.7 %. Seven cases had parotid gland
metastasis and 3 cases had ipsilateral parotid gland
relapse. Patients with level I metastasis and without
level I metastasis showed no significant differences in
3-year and 5-year OS (P = 0.7711). So we suggest that
level I and parotid metastasis should be paid some
attention to, but not be the routine dissected region.
Further studies with larger samples are needed to
address how different metastasis levels affect the out-
come of therapy.The total relapse rate of parotid
gland was 6.5 %. We suggest that we should carefully
assess the lymph nodes in level I and parotid gland
before surgery and selectively dissect level I and
parotid gland in some occasions. However, it may
enhance difficulty and risk of surgery if we routinely
dissect level I and parotid gland. If there are no
metastasized LNs in level I after preoperational evalu-
ation, it is unnecessary to have routine dissection in
this region. If LN residual or relapsed is detected in
parotid region, total parotidectomy and suitable pro-
cedure should be operated. If metastasized LNs in the
upper neck are close to the tail of parotid, partial
parotidectomy should be performed for cervical ND.
Conclusions
Salvage surgery is effective for neck failure of NPC after
primary treatment, but patients with age >50 years or
stage rN3 or LN >6 cm have poor prognosis. MRND is
suitable for most of cases, even if some of them have
ECS. LN in level I and parotid gland do not need neck
dissection, but careful examination is necessary.
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Table 2 Univariate analysis of prognostic factors for OS of 153
patients
Parameter Cases observed OS χ2 value P
3-year (%) 5-year (%)
Age (year)
≤50 90 71.5 55.5
>50 63 39.4 22.8 13.360 0.000
Gender
Male 128 57.1 42.9
Female 25 59.2 23.7 1.401 0.237
Status of LN
Recurrence 105 59.5 43.1
Residue 48 50.9 33.9 1.642 0.200
rN stage
N1 109 67.7 47.0
N2 17 44.9 36.0
N3 27 20.7 15.6 40.152 0.000
Size of LN
≤3 cm 80 67.5 52.4
3~6 cm 47 58.9 34.7
>6 cm 26 21.5 16.2 40.012 0.000
Bilateral of LN
Yes 17 44.9 36.0
NO 136 58.5 40.9 0.005 0.943
ECS
Yes 111 51.8 35.7




Yes 27 54.8 38.4
No 126 57.6 41.0 0.085 0.771
Surgical
procedure
MRND 89 66.3 47.9
RND/ERND 64 44.3 30.5 11.823 0.001
Table 3 Cox regression model of multivariable analysis for OS
Factor β SE Wald P Exp (β)
Age 0.809 0.232 12.193 0.000 2.245
rN stage 0.449 0.186 5.852 0.016 1.567
Size of LN 0.431 0.203 4.527 0.033 1.539
Wang et al. World Journal of Surgical Oncology  (2016) 14:89 Page 5 of 6
Author details
1Department of Oncology, Second Affiliated Hospital, School of Medicine,
Zhejiang University, 88# Jiefang Road, Hangzhou 310009, China.
2Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
310022, People’s Republic of China. 3Department of Head and Neck Surgery,
Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China.
Received: 29 November 2015 Accepted: 29 February 2016
References
1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–54.
2. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent
chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal
carcinoma: positive effect on overall and progression-free survival.
J Clin Oncol. 2003;21:631–7.
3. Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal
carcinoma: current and future directions. Br J Cancer. 2005;92:799–806.
4. Wei WI, Chan JY, Ng RW, Ho WK. Surgical salvage of persistent or recurrent
nasopharyngeal carcinoma with maxillary swing approach-critical appraisal
after 2 decades. Head Neck. 2011;33:969–75.
5. Lee AW, Foo W, Law SC, et al. Nasopharyngeal carcinoma: presenting
symptoms and duration before diagnosis. Hong Kong Med J. 1997;3:355–61.
6. Spano JP, Busson P, Atlan D, et al. Nasopharyngeal carcinomas: an update.
Eur J Cancer. 2003;39:2121–35.
7. Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with
nasopharyngeal carcinoma: an analysis of survival and failure patterns.
Head Neck. 2005;27:555–65.
8. Wei WI, Lam KH, Ho CM, et al. Efficacy of radical neck dissection for the
control of cervical metastasis after radiotherapy for nasopharyngeal
carcinoma. Am J Surg. 1990;160:439–42.
9. Wei WI, Mok VW. The management of neck metastases in nasopharyngeal
cancer. Curr Opin Otolaryngol Head Neck Surg. 2007;15:99–102.
10. Yen KL, Hsu LP, Sheen TS, Chang YL, Hsu MH. Salvage neck dissection for
cervical recurrence of nasopharyngeal carcinoma. Arch Otolaryngol Head
Neck Surg. 1997;123:725–9.
11. Lin CY, Tsai ST, Jin YT, Yang MW, Yeh IC, Hsiao JR. Outcome of surgical
management of persistent or recurrent neck mass in patients with
nasopharyngeal carcinoma after radiotherapy. Eur Arch Otorhinolaryngol.
2008;265 Suppl 1:S69–74.
12. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M.
American Joint Committee on cancer staging manual. 6th ed.
New York: Springer; 2002.
13. Sham JST, Choy D. Nasopharyngeal carcinoma: treatment of neck node
recurrence by radiotherapy. Australas Radiol. 1991;35:370–3.
14. Zhang L, Zhu YX, Wang Y, Huang CP, Wu Y, Ji QH. Salvage surgery for neck
residue or recurrence of nasopharyngeal carcinoma: a 10-year experience.
Ann Surg Oncol. 2011;18:233–8.
15. Wei WI, Ho WK, Cheng AC, et al. Management of extensive cervical nodal
metastasis in nasopharyngeal carcinoma after radiotherapy: a
clinicopathological study. Arch Otolaryngol Head Neck Surg.
2001;127:1457–62.
16. Wei WI. Cancer of the nasopharynx: functional surgical salvage. World J
Surg. 2003;27:844–8.
17. Khafif A, Ferlito A, Takes RP, Thomas RK. Is it necessary to perform radical
neck dissection as a salvage procedure for persistent or recurrent neck
disease after chemoradiotherapy in patients with nasopharyngeal cancer?
Eur Arch Otorhinolaryngol. 2010;267:997–9.
18. Kerawala CJ, Heliotos M. Prevention of complications in neck dissection.
Head Neck Oncol. 2009;1:35.
19. Sham JST, Choy D, Wei WI, et al. Nasoparyngeal carcinoma orderly neck
node spread [J]. Int J Radiat Oncol Biol Phys. 1990;19(8):929–33.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. World Journal of Surgical Oncology  (2016) 14:89 Page 6 of 6
